Mikhail Blagosklonny, renowned cancer and longevity researcher

Who we're talking about: Mikhail Blagosklonny, a renowned oncologist and longevity researcher. Blagosklonny was born and educated in Russia, where he got first his MD and then a PhD in cardiology.

Today, Blagosklonny is Professor of Oncology, Roswell Park Comprehensive Cancer Center, in Buffalo, New York. He is also the editor-in-chief of several scientific journals that cover cancer and longevity research.

One of Blagosklonny's most significant scientific discoveries came in 2006. He discovered that rapamycin, an anti-cancer drug I've covered before in Long Youthspan, is also an exceptionally well-tolerated anti-aging drug.

And the news is: On June 21, Blagosklonny revealed on his personal blog that, earlier this year, he himself was diagnosed with stage 4 lung cancer, which has spread to his brain. Blagosklonny wrote, "As an MD/PhD and professor of oncology, author of 300 articles on cancer progression and therapy, I felt invincible and could not believe that cancer could happen to me."

Why this is a big deal: It's a human tragedy whenever anyone gets diagnosed with stage 4 cancer. Beyond that, from a perspective of morbid scientific interest, Blagosklonny has long been taking rapamycin for its anti-aging effects. He believes rapamycin could be one reason why was able to evade lung cancer for so long, even though an X-ray showed a small mass in his lung all the way back in 1991.

What's next? Blagosklonny is now working on epic article on his site, covering the forefront of anti-cancer research and treatment, longevity, and his personal experience treating cancer. He believes this article is his mission in life.

If you're interested in longevity, or if you have cancer or are close to somebody who does, Blagosklonny’s article might expose you to life-saving information that will be mainstream in 5 or 10 years from now, but which is only on the radar of experts of Blagosklonny's caliber today. In case you're interested, you can find Blagosklonny's developing article here.